Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Angiogenic factors].

A Camez, G Tobelem

    Nouvelle Revue Francaise D'Hematologie
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Tumor angiogenesis, crucial for cancer growth, can be inhibited by factors like heparin. Heparin shows promise in regulating vascular cell growth, offering potential therapeutic strategies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Did animal offer relevant model for Bevacizumab testing?

    British journal of cancer·2008
    Same author

    [Physiologic and neoplastic angiogenesis].

    Journal de chirurgie·2008
    Same author

    Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

    The British journal of dermatology·2007
    Same author

    Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

    The British journal of dermatology·2007
    Same author

    Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha.

    Journal of thrombosis and haemostasis : JTH·2003
    Same author

    Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin.

    Thrombosis research·2001
    Same journal

    XIVth Congress of the French Society of Hematology. Paris, France, February 3-4, 1995. Abstracts.

    Nouvelle revue francaise d'hematologie·1995
    Same journal

    Improved detection of CD2 on formaldehyde-fixed non dehydrated cells.

    Nouvelle revue francaise d'hematologie·1995
    Same journal

    Engraftment of CD34+ peripheral blood progenitor cells into multiple myeloma patients following total body irradiation.

    Nouvelle revue francaise d'hematologie·1995
    Same journal

    Allogeneic transplantation of peripheral blood progenitor cells.

    Nouvelle revue francaise d'hematologie·1995
    Same journal

    Selection and expansion of CD34+ cells.

    Nouvelle revue francaise d'hematologie·1995
    Same journal

    Ex vivo hematopoietic cell expansion: a theoretical and technological challenge.

    Nouvelle revue francaise d'hematologie·1995
    See all related articles

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Context:

    • Angiogenesis, the formation of new blood vessels, is a critical process in tumor progression.
    • Significant research efforts have focused on identifying and characterizing tumor angiogenic factors (TAF).
    • The development of anti-angiogenic therapies is a key area in cancer treatment research.

    Purpose:

    • To review the progress in understanding tumor angiogenesis, from factor identification to therapeutic inhibition.
    • To highlight the role of heparin as a potential inhibitor of angiogenesis.
    • To explore the pharmacological implications of heparin's interaction with growth factors and its effect on vascular cells.

    Summary:

    • Over 14 years, research advanced from identifying tumor angiogenic factors (TAFs) to purifying, sequencing, and cloning a potent TAF.

    Related Experiment Videos

  • Tumor angiogenesis can be effectively inhibited by various agents, including cartilage-derived factors, protamine, and a combination of heparin and cortisone.
  • Heparin demonstrates a significant pharmacological role in angiogenesis by interacting with growth factors and influencing the proliferation of endothelial cells, smooth muscle cells, and fibroblasts.

    • Impact:

    • Understanding the mechanisms of angiogenesis and its inhibition provides a foundation for developing novel cancer therapies.
    • Heparin's demonstrated effects on vascular cell growth suggest its potential as a therapeutic agent in managing angiogenesis-dependent diseases.
    • Further research into heparin's interactions could unlock new strategies for controlling tumor growth and metastasis.